Exelixis’s Q2 Highlights: A Cabozantinib-Driven Topline Lift and a Zanzalintinib Pivot

Snapshot for EXEL (Exelixis, Inc.) and the street’s EPS expectations

Exelixis, Inc. (Nasdaq: EXEL) reported its second-quarter 2026 results with a topline that advanced on a mix of product sales and ongoing pipeline activity. The company books $628.7 million in total revenues for the quarter, up from $568.3 million a year earlier. On the earnings line, GAAP diluted EPS came in at $0.82, while non-GAAP diluted EPS was $0.91. The press release stops short of a formal EPS consensus or a refreshed revenue forecast, which means analysts will be filling in the gaps as they model the quarter-to-quarter trajectory and future milestones.

A large chunk of the revenue is linked to the cabozantinib franchise, which produced $573.0 million of net product revenues in the quarter, versus $520.0 million in the prior-year period. In other words, the core oncology franchise remains the primary driver behind the reported growth, and management emphasizes disciplined expense management alongside capital allocation as it frames the corporate update.

Key numbers at a glance

• Total revenues: $628.7 million
• GAAP diluted EPS: $0.82
• Non-GAAP diluted EPS: $0.91
• Q2 2026 vs Q2 2025 revenues: up from $568.3 million
• Net product revenues (cabozantinib): $573.0 million

Growth drivers: the cabozantinib franchise and a pipeline spotlight

The release foregrounds the cabozantinib franchise as the primary top-line engine, with ongoing strength in U.S. net product revenues. Beyond current results, Exelixis points to strategic progress in its pipeline, notably zanzalintinib—framed as the company’s next potential franchise molecule. Management describes an active R&D agenda geared toward pivotal data readouts, clinical trial enrollment, and new study initiations, all while laying the groundwork for future development opportunities.

The company also flags a regulatory pathway for zanzalintinib in metastatic colorectal cancer, noting a potential launch in the future pending approvals later in 2026. That framing matters because it signals a deliberate shift from pure quarterly execution to longer-range growth optionality, a dynamic investors tend to price into long-duration biotech equities.

Investor event and cadence

Exelixis has scheduled a conference call and webcast for today at 5:00 PM ET to discuss the results. Management and the investor relations team are transparent about milestones and the timetable for the pipeline, but the release does not provide updated guidance or a formal revenue forecast for the remainder of 2026. That omission means the market will rely on commentary around timing, regulatory status, and potential data readouts to calibrate expectations for EPS and revenue in the quarters ahead.

What this portends for EXEL and sector peers

The quarter reinforces a familiar theme in oncology-focused growth names: a strong, product-driven backbone (cabozantinib) paired with optionality from an emerging pipeline. If zanzalintinib progresses toward a pivotal readout or regulatory approval, the stock could see incremental upside tied to the prospect of a second franchise. The absence of explicit EPS consensus or a firm revenue forecast in the release is not unusual for mid-cycle updates, but it nudges analysts to reconcile guidance with the pipeline's timing and potential deal activity.

For sector peers, the message is twofold. First, disciplined cost management and cash generation remain critical as companies balance near-term profitability with long-term R&D bets. Second, the market will reward clarity on regulatory timelines and data-readout milestones. In aggregate, Exelixis’s Q2 underscores a pattern—strong product franchises can fund ambitious pipelines, but the path from a regulatory nod to sustainable revenue growth remains non-linear.

Bottom line

Exelixis delivered a solid quarter with a respectable revenue beat on a year-over-year basis, driven by the cabozantinib franchise. The EPS figures align with a company that remains profitable on a GAAP basis while maintaining a disciplined non-GAAP narrative. The real stock story, however, lies in the pipeline—zanzalintinib could become a meaningful growth vector if regulatory momentum and data readouts align with management’s timeline. For investors and competitors, the coming quarters will hinge on data milestones, regulatory decisions, and how the company monetizes a potential new franchise without sacrificing operating discipline.

In a world of EPS deltas and revenue whispers, Exelixis chooses to balance the math of today with the mystery of tomorrow—keeping the door open for an earnings surprise to surprise on the upside or the downside, depending on how the zanzalintinib story unfolds.